ストックスクリーナーアプリを入手
3.40
5.29%
-0.19
アフターアワーズ：
3.47
0.07
+2.06%
Larimar Therapeutics Inc (LRMR) 最新ニュース
Larimar Therapeutics (LRMR) Slides 3.6%: Technical Support Test in FocusTriple Bottom - newsline.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics (LRMR) Faces Headwinds as Stock Slides 2.21% to $3.10Momentum Surge Alerts - newsline.com
LRMR Q1 2026 Earnings: EPS Surprise of 43% as Loss Narrows, Stock SlidesPost-Announcement Reaction - newsline.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q1 2026 Earnings: EPS Surprise of 43.19% as Net Loss Narrower Than ExpectedProfit Growth Outlook - newsline.com
Larimar Therapeutics (LRMR) Slides 4.3% as Selling Pressure Tests Key SupportFRAMA Signal - newsline.com
Larimar Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Operational ProgressRevenue Warning Signal - newsline.com
Larimar Therapeutics (LRMR): Shares Hold Steady Near Support as Consolidation ContinuesBollinger Band - newsline.com
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Pipeline Progress ContinuesEarnings Forecast Report - thelegaladvocate.com
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9 - Moomoo
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation - MSN
LRMR Initiates Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
JPMorgan Initiates Larimar Therapeutics at Overweight With $9 Price Target - marketscreener.com
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com - Investing.com Australia
JPMorgan initiates Larimar Therapeutics stock at Overweight - Investing.com India
80,590,392 Common Stock of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Stock Options of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Larimar Therapeutics (LRMR) Edges Lower as Stock Tests Key Support ZoneComposite Profile - newsline.com
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria
Larimar Therapeutics stockholders approve board elections and share increase - Investing.com
Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan
LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo
Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail
Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance
Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa
Citizens reiterates Larimar Therapeutics stock rating on FDA progress - Investing.com India
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $15.88, Implies 287% Upside - TradingView
LARIMAR THERAPEUTICS (LRMR) Advances towards Friedreich's Ataxia Treatment Approval - GuruFocus
Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares - Stock Titan
Larimar Therapeutics (LRMR) lifts cash to $200M as FDA grants Breakthrough status - Stock Titan
Larimar Therapeutics 1Q Research and Development Expenses $25.0M >LRMR - Moomoo
Larimar Therapeutics Advances Nomlabofusp for Friedreich’s Ataxia with Rolling BLA Submission and Strong Q1 2026 Financials - Minichart
Larimar Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
LRMR: Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch - TradingView
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update - The Manila Times
Larimar: Q1 Earnings Snapshot - kare11.com
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):